Description

Malignancy with bone metastases is common in patients with advanced tumor like breast cancer, lung cancer, prostate cancer and multiple myeloma. Since patients with breast cancer or prostate cancer have relatively long median survival time, they still face the problem of treating bone metastases. Meanwhile, patients with lung cancer also need to pay attention to bone metastases despite their short median survival due to lung cancer’s high incidence. The complications of bone metastases include bony pain, pathological fracture, spinal cord compression and hypercalcemia. The most common drug for bone metastases is diphosphonate. Three generations of diphosphonate, respectively, etidronate and clodronate representated by Bonefos, pamidronate and alendronate sodium represented by Bonin as well as sodium ibandronate and zoledronic acid are now used in the clinic.

View Full Report at: http://www.marketresearchreports.biz/analysis/294422

Developed by Novartis, zoledronic acid first appeared in the market in Canada in Oct. 2000 and then in May, it entered Britain. In Aug. 2001, it was approved by FDA to be sold under the trade name of Zometa. As the new generation of diphosphonate, zoledronic acid can inhibit the activity of osteoclasts, slow down bone resorption and reduce the incidence of bone metastases in cancer patients. Compared with pamidronate, zoledronic acid is more effective in inhibiting hypercalcemia in patients with multiple myeloma or solid tumor, alleviating pain, delaying bone metastases and other complications.

Each year, the number of new cases of cancer in China reaches more than 3 million, among which about 50% is with bone metastases. Zoledronic acid develops fast after entering China, annual sales value rising from less than CNY 12 million in 2005 to CNY 474 million in 2014 and CAGR during this period reaching 52%. Novartis (Switzerland), Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd, Sichuan Hairong Pharmaceutical Co., Ltd and Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd occupy the majority of the market share, among which Novartis (Switzerland) has the largest market share of over 70% for sales value in 2014.

Download Detail Report With Complete TOC at: http://www.marketresearchreports.biz/sample/sample/294422



Readers can get at least the following information from this report:

market size of zoledronic acid in China
competitive landscape of zoledronic acid in Chinese market
price of zoledronic acid made by different enterprises in China
market outlook of zoledronic acid in China

The author suggests the following groups of people purchase this report:

manufacturers of anti-tumor drugs
investors/ research institutions interested in Chinese medicine market
any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Content

1 Related Concepts of Zoledronic Acid
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Zoledronic Acid in China
2.1 Patent and Approval Status of Zoledronic Acid in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Zoledronic Acid in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

Browse all latest Articles of Market Research Reports
at:http://www.marketresearchreports.biz/articles

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save time and money for our clients.
We are a one stop solution for all your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting services. We serve all sizes and types
of companies spanning across various industries.


Browse Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz


Browse More PressRelease:
http://www.prweb.com/search.aspx?search-releases=marketresearchreports.biz


Contact

Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: [email protected]